Table 5

Summary of efficacy results
Total cohort Peri-operative chemotherapy Surgery alone
n = 51 n = 38 n = 13
Number of patients 51 38 13
Disease-free interval (range) 24.1 months 20.5 months 27.5 months
(2.8-64.1) (11.7-64.1) (2.8-52.8)
Overall survival
Median (95% CI) 77 months (55–99) 91 months (61–121) 67 months (39–96)
3-year (95% CI) 86% (72–93) 85% (68–93) 87% (56–96)
5-year (95% CI) 72% (55–83) 74% (54–86) 68% (35–87)
Relapse free survival
Median (95% CI) 29 months (18–39) 30 months (0–68) 21 months (13–30)
3-year (95% CI) 42% (28–55) 46% (29–61) 38% (12–56)
5-year (95% CI) 31% (18–45) 33% (22–54) ≤18%*
Response to neoadjuvant chemotherapy
n = 39 resections
Complete response 0
Tumour reduction 23 (62%)
Stable disease 11 (30%)
Disease control 34 (92%)
Tumour progression 3 (8%)
No scans available 2

*Not estimable as no events occurred at year 5 and only 1 patient left at risk at year 4 where RFS was estimated at 18%.

Hawkes et al.

Hawkes et al. BMC Cancer 2012 12:326   doi:10.1186/1471-2407-12-326

Open Data